Objectives: To explore the feasibility of multi-isocentric 4p volumetric-modulated arc therapy (MI4p-VMAT) for the complex targets of head and neck cancers.
| INTRODUCTION
IMRT for head and neck cancer (HNC) has been the standard practice for the last decade as it has shown to reduce xerostomia and improve associated quality of life (although such improvement did not resulted statistically significant). 1 Since its introduction in 2008, volumetric-modulated arc therapy (VMAT) has been extensively evaluated for treating HNC. [2] [3] [4] [5] [6] [7] [8] The literature suggests that both treatment efficiency and sparing of organs at risk (OAR) are superior with VMAT compared to conventional static field IMRT (SF-IMRT), although questioned by some authors. 2, 3 Early clinical outcome reports showed comparable toxicity and local control with respect to
IMRT. [4] [5] [6] Advanced planning methods, like knowledge-based automated planning strategies have also been explored to further improve the level of OAR sparing and the harmonization of the results at an interpatient and an interplanner level. 9 Nevertheless, due to the anatomical complexity and several tradeoffs between target coverage and OAR sparing, the use of a simple coplanar approach to the arc geometry setting being currently used seems to leave space for improvement. More recently, some groups explored the possibility to deliver SF-IMRT with conventional c-arm linear accelerators using most of the 4p space, i.e., making extensive use of noncoplanar beam arrangements and creating complex delivery trajectories for the couch-gantry-collimator system around the patient. [10] [11] [12] [13] [14] [15] These investigators focused on stereotactic irradiation in the brain, lungs, and prostate and have shown that significantly sharper dose gradients can be achieved with this approach. These studies concluded that the 4p technique reduced mean or maximum doses to all OAR and may allow for safe dose escalation. The original investigations published provided evidence of benefit and proof of principle for smaller tumors. A study involving the 4p approach to SF-IMRT for HNC was also attempted but it was for small and recurrent cancers. 16 The question of applicability of 4p techniques to truly large target volumes and its feasibility for conventional IMRT/VMAT treatments remains unaddressed for HNC. The aim of this study was to explore multi-isocentric 4p volumetric-modulated arc therapy (MI4p-VMAT) plans in terms of dosimetry and delivery and comparing it with best coplanar VMAT(CP-VMAT) plans for the irradiation of HNC patients characterized by large targets and the presence of several organs at risk. Deliverability was addressed in terms of dosimetric accuracy. In the absence of an automated collision avoidance engine, this aspect was qualitatively addressed with the pretreatment quality assurance procedures performed with a body phantom.
| MATERIALS AND METHODS
Institutional scientific and ethics board approved this study. Twentyfive previously treated HNC patients with two coplanar volumetric arcs (CP-VMAT) were included in a retrospective preclinical planning study. Patient characteristics are summarized in Table 1 . For each patient, the gross tumor volume (GTV) was defined as the macroscopic tumor seen on imaging, while the clinical tumor volumes (CTVs) were defined as per standard institutional practice for HNC.
CTV nodal volumes were defined as per standard RTOG protocol. 17 Planning target volume (PTV) was generated by isotropic expansion of CTV by 0.5 cm. Each PTV was defined as the mutual subtraction of each other, so they were not mutually including each other. For all the patients, the following organs at risk were defined: parotids, oral cavity, esophagus, trachea, larynx, pharyngeal muscles, mandible, temporomandibular joint, middle ear, spinal cord, and brain stem. For the spinal cord, the near-to-maximum dose constraint was set to 45 Gy to 1% of its volume (50 Gy for the brain stem). For the parotids, the mean dose was aimed to be lower than 32 Gy. For the other structures, the planning strategy was to minimize as much as reasonably possible their involvement. Standard dose prescription was used (PTV-high: 70 Gy, PTV-mid: 60/63 Gy and PTV-low: 56 Gy). 10-20°a ccording to the patients anatomy. The CP-VMAT plans were reoptimized starting from the clinically accepted ones to improve the reference dose distributions. Aims were to achieve the highest possible dose conformity to the target with the least involvement of the organs at risk. Multiple planners calculated the CP-VMAT plans but the selection of the final plan was made on a shared consensus. The optimal plans were selected in terms of numerical plan quality metrics, these were the ones with the "best" results for each of the planning dose-volume objectives. No knowledge-based planning tools were applied since not available at the clinic.
MI4p-VMAT plans were optimized using the same objectives and priorities as the co-planar ones. Plan geometry consisted of 3-6 arcs with 2-3 isocenters which were manually selected to avoid any risk of collisions (and verified qualitatively during the pretreatment dosimetric verification with the body phantom) which might occur during the noncoplanar arc trajectory. Extreme care was taken to assign isocenters such that there was a minimum of 10 cm clearance between the patient and gantry-collimator system as well as between the collimator and couch surfaces to avoid risks of collisions. For each patient, MI4p-VMAT plan geometry was validated for delivery by simulating the planned field geometry with their immobilization system and actual isocenters at place. This simulation also ruled out the possibility of collision during noncoplanar arc trajectories. The typical field geometry for an example case is illustrated in Fig. 1 . The average total arc length for twenty-five MI4p-VMAT plans was 1115 AE 228 degrees with a maximum of 1358 degrees.
All the plans had one full coplanar arc in addition to the noncoplanar arcs. Typical field geometry consisted of one full-arc with couch angle 0 degree, two partial arcs (arc length of AE 210°) with average couch rotation of AE 45°, and two more partial arcs (arc length of 
Germany) without resetting couch, gantry and collimator and isocenters. Omnipro IMRT QA software (IBA dosimetry, GmbH, Germany) was used to perform global gamma agreement index (GAI) analysis with criteria of 3 mm distance to agreement (DTA) and 3% dose difference (DD). GAI was used to quantify the agreement between the predicted and measured dose distribution at the isocenter plane. Figures 2 and 3 show the DVH parameters for PTV and OAR depicting the best CP-VMAT and MI4p-VMAT plan comparison. Figure 4 shows the typical dose distributions of both the techniques in axial, coronal, and sagittal planes for a patient. The color-wash display is set to 5-70 Gy to display the dose bath and to 48-70 Gy to display dose conformality.
| RESULTS
From the qualitative inspection of the DVHs, the target coverage was similar between the best CP-VMAT and MI4p-VMAT plans with respect to conformity, homogeneity, and percentage doses. However, when the OAR doses were compared, the MI4p-VMAT plans delivered significantly less dose to various relevant OAR. There was significant reduction in average mean doses with MI4p-VMAT plans with respect to bilateral parotids by 3 Gy, oral cavity by 5 Gy, 
| DISCUSSION
There is a perception that current IMRT and VMAT techniques have hit a plateau with respect to physically achievable dose distributions.
One of the techniques that challenge this perception is the 4p approach, which involves the use of multiple noncoplanar beams using robotic couch and gantry on modern C-arm linear accelerators.
The studies from the University of California (Los Angeles, UCLA) have elegantly described this technique and have demonstrated significant sparing of OAR and discussed the potential for dose escalation in patients of lung, liver, prostate, HNC, and brain tumors. TrueBeam system) might have sub-mm accuracy in their rotational axes which could mitigate these risks. 19 A dedicated study about the robustness of the plans against the table rotation errors is out of the scope of this investigation and should be considered as a follow-up study. Depending on the equipment and staff, this can require amendments in the CTV-PTV margin definitions or other mitigation strategies. However, simple planar MV imaging can be performed which could further decrease the treatment efficiency.
Another limitation of the study is the use of a global 3% 3 mm criterion for the gamma analysis, which might hide finer discrepancies. Nevertheless, the criteria applied are the standard used for clinical practice and are appropriate for the large volumes involved in the study.
| CONCLUSION
The results from our study show the dosimetric performance and feasibility of MI4p-VMAT for HNC. Compared with CP-VMAT plans, all dose-volume metrics of relevant OAR decreased significantly without altering dose conformity for relatively large and complex PTV volumes.
These plans are clinically deliverable with acceptable quality assurance.
The improvements in hardware and availability of MI4p-VMAT optimization algorithm with automated delivery can further improve the quality of plans as well as enhance treatment efficiency and thereby making it possible for this technique to be adopted for routine day-today clinical practice. Early clinical experience has begun and future studies will aim to report treatment outcomes.
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